{"nct_id":"NCT01974440","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","status_verified_date":"2025-05","start_date":"2014-01-31","start_date_type":"ACTUAL","primary_completion_date":"2022-05-30","primary_completion_date_type":"ACTUAL","completion_date":"2023-06-21","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["JNJ"]}